Beta-Blocker Landiolol Hydrochloride in Preventing Atrial Fibrillation Following Cardiothoracic Surgery: A Systematic Review and Meta-Analysis

Objective: The purpose of this article was to assess the benefit of perioperative administration of the intravenous beta-blocker landiolol hydrochloride in preventing atrial fibrillation (AF) after cardiothoracic surgery.Methods: We performed a systematic search in PubMed, Web of Science, CNKI, and...

Full description

Saved in:
Bibliographic Details
Published in:Annals of Thoracic and Cardiovascular Surgery 2022, Vol.28(1), pp.18-31
Main Authors: Hao, Jianqi, Zhou, Jian, Xu, Wenying, Chen, Cong, Zhang, Jian, Peng, Haoning, Liu, Lunxu
Format: Article
Language:English
Subjects:
atrial fibrillation
Atrial Fibrillation - diagnosis
Atrial Fibrillation - etiology
Atrial Fibrillation - prevention & control
cardiothoracic surgery
Humans
landiolol
Morpholines - adverse effects
postoperative complications
Postoperative Complications - epidemiology
Postoperative Complications - etiology
Postoperative Complications - prevention & control
Review
Treatment Outcome
Urea - analogs & derivatives
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: The purpose of this article was to assess the benefit of perioperative administration of the intravenous beta-blocker landiolol hydrochloride in preventing atrial fibrillation (AF) after cardiothoracic surgery.Methods: We performed a systematic search in PubMed, Web of Science, CNKI, and OVID to identify randomized controlled trials (RCTs) and cohorts up to January 2021. Data regarding postoperative atrial fibrillation (POAF) and safety outcomes were extracted. Odds ratios (ORs) with 95% confidence intervals (CIs) were determined using the Mantel–Haenszel method. Meanwhile, subgroup analyses were conducted according to surgery type including lung cancer surgery, esophageal cancer surgery, and cardiac surgery.Results: Seventeen eligible articles involving 1349 patients within 13 RCTs and four cohorts were included in our meta-analysis. Compared with control group, landiolol administration was associated with a significant reduction of the occurrence of AF after cardiothoracic surgery (OR = 0.32, 95% CI 0.23–0.43, P
ISSN:1341-1098
2186-1005
DOI:10.5761/atcs.ra.21-00126